Apricoxib

Apricoxib
Systematic (IUPAC) name
4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
Identifiers
CAS Number 162011-90-7
PubChem CID 9820073
ChemSpider 7995822
Chemical data
Formula C19H20N2O3S
Molar mass 356.4387 g/mol

Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.[1]

See also

References

  1. Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453.


This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.